US Patent Issued to NANJING IMMUNOPHAGE BIOTECH on Dec. 16 for "ROR1 specific chimeric antigen receptors and their therapeutic applications" (Chinese Inventors)

ALEXANDRIA, Va., Dec. 16 -- United States Patent no. 12,497,453, issued on Dec. 16, was assigned to NANJING IMMUNOPHAGE BIOTECH Co. LTD. (Nanjing, China).

"ROR1 specific chimeric antigen receptors and their therapeutic applications" was invented by Guohuang Fan (Shanghai) and Jianfei Wang (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides ROR1 specific chimeric antigen receptors (CAR) and their therapeutic use. The CAR comprises a signal peptide, a ROR1 antigen binding domain, a hinge, a transmembrane domain, a co-stimulatory domain and an intracellular signaling domain. The modified immune cells endowed with such CARs are suitable for treating malignancies such as cancer...